Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Mould

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|October 20, 2015
Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this?D R Mould
Clinical Pharmacology and Therapeutics|May 24, 2012
Models for disease progression: new approaches and usesD R Mould
Clinical Pharmacology and Therapeutics|August 23, 2012
Model-based meta-analysis: an important tool for making quantitative decisions during drug developmentD R Mould
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
Basic concepts in population modeling, simulation, and model-based drug developmentD R Mould, R N Upton
CPT: Pharmacometrics & Systems Pharmacology|January 4, 2014
Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methodsR N Upton, D R Mould
Analytical Biochemistry|February 15, 1991
Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modificationsS D Black, D R Mould
CPT: Pharmacometrics & Systems Pharmacology|July 27, 2013
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methodsD R Mould, R N Upton
Clinical Pharmacology and Therapeutics|February 11, 2017
The Role of FcRn in the Pharmacokinetics of Biologics in Patients With Multiple MyelomaJ F M Jacobs, D R Mould
Clinical Pharmacology and Therapeutics|May 18, 2007
Using disease progression models as a tool to detect drug effectD R Mould, N G Denman, S Duffull
Clinical Pharmacology and Therapeutics|January 20, 2016
Clinical Decision Support Tools: The Evolution of a RevolutionD R Mould, G D'Haens, R N Upton
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|October 20, 2015
Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this?D R Mould
Clinical Pharmacology and Therapeutics|May 24, 2012
Models for disease progression: new approaches and usesD R Mould
Clinical Pharmacology and Therapeutics|August 23, 2012
Model-based meta-analysis: an important tool for making quantitative decisions during drug developmentD R Mould
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
Basic concepts in population modeling, simulation, and model-based drug developmentD R Mould, R N Upton
CPT: Pharmacometrics & Systems Pharmacology|January 4, 2014
Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methodsR N Upton, D R Mould
Analytical Biochemistry|February 15, 1991
Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modificationsS D Black, D R Mould
CPT: Pharmacometrics & Systems Pharmacology|July 27, 2013
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methodsD R Mould, R N Upton
Clinical Pharmacology and Therapeutics|February 11, 2017
The Role of FcRn in the Pharmacokinetics of Biologics in Patients With Multiple MyelomaJ F M Jacobs, D R Mould
Clinical Pharmacology and Therapeutics|May 18, 2007
Using disease progression models as a tool to detect drug effectD R Mould, N G Denman, S Duffull
Clinical Pharmacology and Therapeutics|January 20, 2016
Clinical Decision Support Tools: The Evolution of a RevolutionD R Mould, G D'Haens, R N Upton
Pageof 3